A Phase 1b2a Trial of a Halflife Extended Respiratory Syncytial Virus Neutralizing Antibody Clesrovimab in Healthy Preterm and Fullterm Infants
Loading...
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Description
Keywords
Citation
WOS